Tylosin is used in farm animals for a variety of purposes, as a dietary supplement to promote growth and as an antibiotic against infectious diseases in animals such as chickens, turkeys, cats, dogs, pigs, calves, and others. These antibiotics help treat chronic respiratory disease (CKD) related to Mycoplasma gallisepticum and Mycoplasma synoviae and other infections. Tylosin is used to treat and control porcine dysentery related to Brachyspira Hyodysenteriae and to control porcine proliferative enteropathies in pigs. In dogs, chronic and recurrent canine diarrhea has a repetitive response to tylosin treatment.
Over the forecast period (2018-2026), the market size was estimated at $379.0 million.
The Tylosin market is expected to grow significantly during the forecast period due to the increasing demand for Tylosin in the livestock industry. Interestingly, according to one study cited in this paragraph, tylosin sales displaced macrolides and lincosamides during 2011 and 2014, and this trend appears to be persisting. A number of mergers and acquisitions are also expected to drive market growth during the forecast period. Novartis Animal Health was acquired by Eily, Lilly, and Company in 2014. Due to the presence of manufacturers such as Elanco Animal Health, Tylosin's wide product portfolio is likely to drive growth in the global tylosin market over the forecast period. Examples of Elanco's lead-Dylan implants for oxen and heifers include those for cows. Antibacterial agents are released by Tylosin tartrate pellets (Tylan) in the implantation site.